References
- Breccia M, Latagliata R, Mengarelli A, . Prognostic factors in myelodysplastic and myeloproliferative types of chronic myelomonocytic leukemia: a retrospective analysis of 83 patients from a single institution. Haematologica 2004;89:866–868.
- Onida F, Kantarjian HM, Smith TL, . Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002;99:840–849.
- Beran M, Wen S, Shen Y, . Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M. D. Anderson Prognostic Scoring System. Leuk Lymphoma 2007;48:1150–1160.
- Braun T, Itzykson R, Renneville A, . Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood 2011;118:3824–3831.
- Kantarjian H, Issa JP, Rosenfeld CS, . Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:1794–1803.
- Fenaux P, Mufti GJ, Hellstrom-Lindberg E, . Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223–232.
- Costa R, Abdulhaq H, Haq B, . Activity of azacitidine in chronic myelomonocytic leukemia. Cancer 2011;117:2690–2696.
- Tsai HC, Li H, Van Neste L, . Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 2012;21:430–446.
- Thorpe M, Montalvão A, Pierdomenico F, . Treatment of chronic myelomonocytic leukemia with 5-azacitidine: a case series and literature review. Leuk Res 2012;36:1071–1073.
- Aribi A, Borthakur G, Ravandi F, . Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer 2007;109:713–717.
- Kohlmann A, Grossmann V, Klein HU, . Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 2010;28:3858–3865.
- Pérez C, Martínez-Calle N, Martín-Subero JI, . TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia. PLoS One 2012;7:e31605.
- Ko M, Huang Y, Jankowska AM, . Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010;468:839–843.
- Itzykson R, Kosmider O, Cluzeau T, . Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011;25:1147–1152.
- Voso MT, Fabiani E, Piciocchi A, . Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine. Leukemia 2011;25:1910–1913.